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Endoleak, the Achilles heel of endovascular aortic aneurysm repair
(EVAR), is correlatedwith aneurysm sac expansion, the need for conver-
sion, aneurysm rupture, and death. The presence of endoleak is the
most common reason for readmission to the hospital after EVAR and
increases the secondary procedure rate, cost, and length of stay.
Collateral vessel endoleaks (type II), the most prevalent form
of endoleaks, do not behave as a uniform class even though they
share a common etiology—back bleeding from an aortic branch.
As Silverberg et al and others have demonstrated, some of these
leaks will spontaneously thrombose, and some will persist. Some
will transmit systemic pressure to the aneurysm sac and to lead to
rupture of the aneurysm, whereas in other cases, the aneurysm sac
regresses and the patients seem to be protected from aneurysm
rupture despite the presence of an endoleak. Unlike type I and type
III endoleaks, which mandate repair upon their discovery, there is
no clear consensus on how type II endoleaks should best be
treated, or even monitored.
Why are type II endoleaks so different and unpredictable in
their behavior? Vascular surgeons readily understand that type II
endoleaks could not remain patent if only supplied by a single
vessel, because end arteries with no outflow rapidly thrombose.
This explains why most type II endoleaks that are detected imme-
diately postoperatively have disappeared by the time of the first
postoperative computed tomography (CT) scan. For a branch
vessel endoleak to remain patent, it must have both inflow and
outflow. Duplex Doppler ultrasound criteria, which have been
found to be predictive of type II endoleak thrombosis, include a
high-resistance type of flow, whereas what is most predictive of
continuation of the endoleak is a low-resistance, continuous type
flow, indicative of a patent outflow tract. The flow patterns in these
endoleaks are variable, changing with blood pressure, position,
respiration, and other dynamic factors.
This changing flow pattern presents a great challenge to
current imaging modalities and explains the frequent observation
of “intermittent appearance” of a type II endoleak. CT angiogra-
phy (CTA) has been shown repeatedly to lack specificity for
determination of leak type and vessel origin of type II leaksthe sac in patients who have been found to have a type II endoleak
often reveals multiple pairs of lumbar arteries in communication
with each other as well as with other branch vessels, when only a
single vessel was suspected by the screening CTA images.
The emerging understanding of these endoleaks is a picture
analogous to our view of arteriovenous malformations. They are
associated with multiple vessels, which may serve as inflow or
outflow, depending on the prevailing physiologic state at the
moment. The involved vessels share a nidus of communication that
maintains the patency of the type II endoleak.
Treatment of type II endoleaks should focus on disruption of
this nidus, resulting in end arteries without the possibility of
outflow, leading to thrombosis. For this reason, it is no wonder
that type II endoleaks related to patent lumbar arteries developed
in all 12 (100%) of the patients Silverberg et al treated by means of
preoperative inferior mesenteric artery (IMA) embolization! Their
prophylactic strategy addressed individual feeding arteries rather
than the root cause of the endoleak, which is the communication
between multiple arteries. If a prophylactic approach to type II
endoleak is to be developed, the greatest likelihood for success
would likely be to focus on obliteration of the sac and the paths
between branch vessels.
Silverbergetalhavetakenamostly selectiveapproachto intervention
for type II endoleaks, with the notable exception of the previously
mentioned preoperative IMA embolizations, generally reserving inter-
vention for patients who demonstrate significant sac expansion. They
have shown that in the short term (22 months’ mean follow-up), this
approachhasnot resulted inanyaneurysmruptures.Because theydidnot
apply any standard protocol to the treatment of type II endoleak, and in
the absence of a control group for comparison, it is difficult to determine
if the behavior of their endoleak patients is different from that of EVAR
patients in general or even from the natural history of untreated
aneurysms over a 22-month mean follow-up interval. No clear treat-
ment recommendations emerge.
What is clear is that our understanding of type II endoleak and its
treatment is evolving. Patients remain at risk for development of en-
doleaks at all times after EVAR. This is an absolute mandate for contin-
ued, careful surveillance of patients who have undergone EVAR.
